GALAPAGOS NV |
Market Closed -
Other stock markets
|
After market 01:29:55 am | |||
| 27.4 EUR | +1.86% |
|
27.37 | -0.11% |
| 07:03am | Galapagos Partners with Blood Centers of America to Decentralize CAR-T Cell Therapy Manufacture | MT |
| 03/05 | Transcript : Galapagos NV, Q1 2024 Earnings Call, May 03, 2024 |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 313M 340M 28.38B | Sales 2025 * | 302M 329M 27.43B | Capitalization | 1.81B 1.96B 164B |
|---|---|---|---|---|---|
| Net income 2024 * | -13M -14.13M -1.18B | Net income 2025 * | -71M -77.15M -6.44B | EV / Sales 2024 * | -4.99 x |
| Net cash position 2024 * | 3.37B 3.66B 305B | Net cash position 2025 * | 2.97B 3.23B 270B | EV / Sales 2025 * | -3.86 x |
| P/E ratio 2024 * |
-23
x | P/E ratio 2025 * |
-17.6
x | Employees | 1,123 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.64% |
More Fundamentals
* Assessed data
More news
Latest transcript on Galapagos NV
More recommendations
More press releases
More news
| 1 day | +1.86% | ||
| 1 week | +1.41% | ||
| Current month | +3.09% | ||
| 1 month | -2.63% | ||
| 3 months | -25.24% | ||
| 6 months | -21.11% | ||
| Current year | -25.93% |
1 week
26.30
28.42
1 month
26.3028.42
Current year
26.3039.00
1 year
26.3041.92
3 years
26.3066.86
5 years
26.30252.90
10 years
10.00252.90
| Managers | Title | Age | Since |
|---|---|---|---|
Paulus Stoffels
CEO | Chief Executive Officer | 62 | 01/22/01 |
Thad Huston
DFI | Director of Finance/CFO | 54 | 01/23/01 |
| Investor Relations Contact | - | 01/20/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Andrew Dickinson
BRD | Director/Board Member | 54 | 27/03 |
Jérôme Contamine
BRD | Director/Board Member | 66 | 26/22/26 |
Simon Sturge
BRD | Director/Board Member | 65 | 19/23/19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.28% | 21 M€ | +3.64% | ||
| 0.03% | 746 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/24/16 | 27.4 | +1.86% | 253 098 |
| 15/24/15 | 26.9 | +1.82% | 61,742 |
| 14/24/14 | 26.42 | -0.53% | 66,095 |
| 13/24/13 | 26.56 | -0.38% | 75,616 |
| 10/24/10 | 26.66 | -0.60% | 44,236 |
Real-time Euronext Amsterdam, May 16, 2024 at 09:05 pm IST
More quotes
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. The company is committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.
Calendar
01/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
27.4
EUR
Average target price
37.03
EUR
Spread / Average Target
+35.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -25.93% | 1.93B | |
| +33.37% | 49.46B | |
| +1.55% | 42.58B | |
| +49.11% | 42.49B | |
| -4.22% | 29.09B | |
| +11.57% | 26.61B | |
| -21.00% | 18.64B | |
| +7.36% | 13.16B | |
| +28.30% | 12.55B | |
| +23.80% | 12.1B |
- Stock Market
- Equities
- GLPG Stock
